Tag Archives: Auto-Injectors Market

New Applications and Products Leading Auto-Injectors Market with Big CAGR

Auto-injectors are used for the administration of a single dose of a particular (typically life-saving) drug. They are designed for easy use and intended for self administration or administration by any untrained personnel.

This report provides an in-depth analysis of the global auto-injectors market. The stakeholders for this report include companies engaged in research and development, manufacturing, distribution, and commercialization of auto-injectors, and new entrants planning to invest in the auto-injectors market. The executive summary section of this report provides a snapshot of the auto-injectors market, which summarizes the market size, trends, and competition for different types of auto-injectors for various therapeutic applications on the global front.

This 89 page report gives readers a comprehensive overview of the Auto-injectors Market . Browse through 6 data tables and 29 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/global-auto-injectors-market.html

The market overview section elucidates market dynamics such as drivers, restraints, and opportunities that currently have strong influence over the auto-injectors market and could impact the future scenario of the market as well. Market attractiveness analysis has been included in the market overview section in order to explicate the degree of competition among major geographies.

Porter’s five forces analysis is also incorporated in this section to explore the overall competition in the auto-injectors market, considering five different parameters that have an effect on the sustainability of companies in the market. The regulatory framework section highlights the standards and recommendations, set by various government organizations worldwide, which have strong impact on the auto-injectors market. Competition between major market players is analyzed along with their market share analysis in the competitive landscape section of the report. Value chain analysis has been provided to recognize the value-creating activities from a number of processes that take place in transforming inputs to valuable outputs. Event mapping is done for a brief understanding of the technological advancements, new product launches, and strategic decisions taken by players in the global auto-injectors market. All these factors assist the market players in taking strategic decisions, which help them in escalating their market share and strengthening their positions in the global auto-injectors market.

The global auto-injectors market has been segmented on the basis of product, therapeutic applications, and manufacturing design. Based on product type, the global auto-injectors market is classified into two major segments, namely prefilled auto-injectors and fillable auto-injectors. Based on therapeutic applications, the auto-injectors market is differentiated into four segments: anaphylaxis, multiple sclerosis, rheumatoid arthritis, and others. Depending upon the manufacturing design, the global auto-injectors market is categorized into two segments: standardized auto-injectors and customized auto-injectors. Market revenue in terms of USD million for the period between 2012 and 2020 along with the compound annual growth rate (CAGR %) from 2014 to 2020 are provided for all segments, considering 2013 as the base year.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Auto-injectors Market during 2014 – 2020

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

Geographically, the global auto-injectors market has been segmented into four regional markets: North America, Europe, Asia Pacific, and Rest of the World (RoW). This section of the report provides market estimations in terms of revenue (USD million) of auto-injectors across four regions from 2012 to 2020. CAGR % for the period from 2014 to 2020 is also analyzed for these four geographies, considering 2013 as the base year.

This report also includes recommendations that would help new market entrants in establishing presence and existing market players in expanding their global reach and market share in the auto-injectors market. The report concludes by profiling major players in the auto-injectors market. Company overview, financial overview, product portfolio, business strategy, and recent developments are provided for major market players in the company profile section. Major market players profiled in the report include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Mylan, Inc., Novartis International AG, Pfizer, Inc., Sanofi, Scandinavian Health Limited (SHL) Group, Unilife Corporation, and Ypsomed Holdings AG.

Auto Injectors Market Offering High-growth Opportunities for Market Players

Auto-injectors are hypodermic syringes used to administer a single dose of a drug (typically any life saving drug). These are easy to use and are intended either for self-administration or by untrained personnel. The commercially available auto-injectors are majorly used for the management of anaphylaxis, multiple sclerosis and rheumatoid arthritis. High prevalence of anaphylaxis and food allergies is the major factor propelling the growth of the global auto-injectors market. According to the European Academy of Allergy and Clinical Immunology (EAACI), there has been a seven-fold increase in anaphylaxis related hospital admissions in Europe from 2003 to 2013. Similarly, the Australasian Society of Clinical Immunology and Allergy (ASCIA) stated that the number of anaphylaxis associated hospital admissions increased five times from 2004 to 2014 in New Zealand and Australia. Rising prevalence of anaphylaxis and food allergies is increasing the demand for epinephrine auto-injectors used for anaphylaxis management. Moreover, Healthline Networks, a provider of health information and technology solutions for advertisers, publishers, employers, and health plans and healthcare providers, stated that 2.5 million people were suffering from multiple sclerosis in 2013 worldwide. High prevalence of multiple sclerosis and rheumatoid arthritis is increasing the demand for novel treatment options among the patients, which in turn drives demand for auto-injectors globally.

This 89 page report gives readers a comprehensive overview of the Auto-injectors Market . Browse through 6 data tables and 29 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/global-auto-injectors-market.html

Based on product types, the global auto-injectors market has been categorized into prefilled auto-injectors and fillable auto-injectors. Prefilled auto-injectors dominate the auto-injectors market due to their offered ease-of-use and rising patient awareness. Based on Therapeutic Applications, the global auto-injectors market has been segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The anaphylaxis segment was the leading and fastest growing market majorly due to high prevalence of the disease, rising awareness about epinephrine auto-injectors and advantages of its use for anaphylaxis management during emergency situations. Based on the manufacturing design, the auto-injectors market has been segmented into standardized auto-injectors and customized auto-injectors. Standardized auto-injectors dominated the market in 2013, as these are the oldest and most preferred auto-injectors with an established record of effective results. However, customized auto-injectors is estimated to be the fastest growing segment, as these offer customization of the dosage of the drug according to age, sex and need of the patient.

Geographically, the global auto-injectors market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global auto-injectors market in 2013 due to high prevalence of anaphylaxis, favorable government reimbursement policies and economic stability to purchase expensive auto-injectors in the region. On the other hand, Asia Pacific is estimated to be the most promising market for auto-injectors during the forecast period due to rising prevalence of anaphylaxis and multiple sclerosis in New Zealand and Australia coupled with the government reimbursement options in New Zealand, and rising awareness about novel treatment methods available in the market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Auto-injectors Market during 2014 – 2020

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

The auto-injectors market is consolidated and dominated by a few market players. Mylan, Inc. and Sanofi led the standardized auto-injectors segment due to higher demand for EpiPen and Auvi-Q auto-injectors, respectively. However, the SHL Group dominated the customized auto-injectors segment, with a wide product offering of prefilled customized auto-injectors. The other major companies operating in the auto-injectors market include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Novartis International AG, Pfizer, Inc., Unilife Corporation and Ypsomed Holdings AG. The auto-injectors market is innovation driven, therefore market players are constantly engaged in research and development activities in order to develop new and effective auto-injectors against various diseases.

 

Auto-Injectors Market to Expand at 18.6% CAGR from 2014 to 2020

Transparency Market Research (TMR) has recently published a report on the global auto-injectors market, according to which, the market is expected to expand at a remarkable CAGR of 18.60% between 2014 and 2020.The research report, titled “Auto-Injectors Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” projects this market to increase from a value of US$0.6 bn in 2013 to US$2.5 bn by the end of the forecast period.

Auto-injectors are mostly spring-loaded syringes used for injecting oneself with a preloaded, single dose of a drug. These injectors are easy to use and are generally utilized in the case of multiple sclerosis, anaphylaxis, or rheumatoid arthritis. The growing prevalence of anaphylaxis and allergies from food have fueled the demand for auto-injectors globally. Apart from this, the implementation of favorable reimbursement policies by various governments across the world is also propelling this market significantly.

 This 89 page report gives readers a comprehensive overview of the Auto-injectors Market . Browse through 6 data tables and 29 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/global-auto-injectors-market.html

The research report presents an in-depth analysis of the global market for auto-injectors. It studies the market on four fronts: The type of product, manufacturing design, application, and the region. Based on the type of product, the market has been categorized into fillable (reusable) auto-injectors and prefilled (disposable) auto-injectors. The prefilled auto-injectors segment enjoys a higher demand than the fillable auto-injectors segment on account of the ease of usage provided by prefilled auto-injectors.

By manufacturing design, the market has been classified into standardized auto-injectors and customized auto-injectors. The standardized auto-injectors segment dominated the overall market in 2013. However, analysts anticipate the customized auto-injectors segment to record the fastest growth during the forecast period, states the report.

Application-wise, the market has been grouped into rheumatoid arthritis, multiple sclerosis, anaphylaxis, and other applications. In 2013, the demand for auto-injectors was the highest from the anaphylaxis segment.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Auto-injectors Market during 2014 – 2020

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

Regionally, the research report has segmented the worldwide market for auto-injectors into North America, Asia Pacific, Europe, and the Rest of the World. North America led the global market in 2013 with a share of 70%. The increased prevalence of anaphylaxis and the rise in the disposable income of individuals, enabling them to afford expensive treatments, have fueled the demand for auto-injectors in this region significantly. The presence of a favorable reimbursement environment has also boosted this regional market in the recent past.

Asia Pacific, however, is projected to emerge as the most promising regional market for auto-injectors over the forecast period. The rising incidence of multiple sclerosis and anaphylaxis in Australia and New Zealand, together with favorable reimbursement options in New Zealand, is likely to propel this regional market considerably during the forecast period. The growing awareness regarding novel treatment methods and increasing disposable income of people are also expected to drive the Asia Pacific auto-injectors market in the coming years, notes the research study.

Ypsomed Holding AG, Unilife Corp., Scandinavian Health Ltd., Sanofi, Novartis International AG, Mylan Inc., Biogen Idec, Becton, Dickinson & Co., and Antares Pharma Inc. are the major international players in the global auto-injectors market profiled in this market report.

 

Auto Injectors Market Offering High-growth Opportunities for Market Players

Auto-injectors are hypodermic syringes used to administer a single dose of a drug (typically any life saving drug). These are easy to use and are intended either for self-administration or by untrained personnel. The commercially available auto-injectors are majorly used for the management of anaphylaxis, multiple sclerosis and rheumatoid arthritis. High prevalence of anaphylaxis and food allergies is the major factor propelling the growth of the global auto-injectors market. According to the European Academy of Allergy and Clinical Immunology (EAACI), there has been a seven-fold increase in anaphylaxis related hospital admissions in Europe from 2003 to 2013. Similarly, the Australasian Society of Clinical Immunology and Allergy (ASCIA) stated that the number of anaphylaxis associated hospital admissions increased five times from 2004 to 2014 in New Zealand and Australia. Rising prevalence of anaphylaxis and food allergies is increasing the demand for epinephrine auto-injectors used for anaphylaxis management. Moreover, Healthline Networks, a provider of health information and technology solutions for advertisers, publishers, employers, and health plans and healthcare providers, stated that 2.5 million people were suffering from multiple sclerosis in 2013 worldwide. High prevalence of multiple sclerosis and rheumatoid arthritis is increasing the demand for novel treatment options among the patients, which in turn drives demand for auto-injectors globally.

Read Full Report: http://www.transparencymarketresearch.com/global-auto-injectors-market.html

Based on product types, the global auto-injectors market has been categorized into prefilled auto-injectors and fillable auto-injectors. Prefilled auto-injectors dominate the auto-injectors market due to their offered ease-of-use and rising patient awareness. Based on Therapeutic Applications, the global auto-injectors market has been segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The anaphylaxis segment was the leading and fastest growing market majorly due to high prevalence of the disease, rising awareness about epinephrine auto-injectors and advantages of its use for anaphylaxis management during emergency situations. Based on the manufacturing design, the auto-injectors market has been segmented into standardized auto-injectors and customized auto-injectors. Standardized auto-injectors dominated the market in 2013, as these are the oldest and most preferred auto-injectors with an established record of effective results. However, customized auto-injectors is estimated to be the fastest growing segment, as these offer customization of the dosage of the drug according to age, sex and need of the patient.

Geographically, the global auto-injectors market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global auto-injectors market in 2013 due to high prevalence of anaphylaxis, favorable government reimbursement policies and economic stability to purchase expensive auto-injectors in the region. On the other hand, Asia Pacific is estimated to be the most promising market for auto-injectors during the forecast period due to rising prevalence of anaphylaxis and multiple sclerosis in New Zealand and Australia coupled with the government reimbursement options in New Zealand, and rising awareness about novel treatment methods available in the market.

Get a Sample for this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

The auto-injectors market is consolidated and dominated by a few market players. Mylan, Inc. and Sanofi led the standardized auto-injectors segment due to higher demand for EpiPen and Auvi-Q auto-injectors, respectively. However, the SHL Group dominated the customized auto-injectors segment, with a wide product offering of prefilled customized auto-injectors. The other major companies operating in the auto-injectors market include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Novartis International AG, Pfizer, Inc., Unilife Corporation and Ypsomed Holdings AG. The auto-injectors market is innovation driven, therefore market players are constantly engaged in research and development activities in order to develop new and effective auto-injectors against various diseases.

 

Leading Players in Auto Injectors Market

syringe-145002_640

Auto-injectors are hypodermic syringes used to administer a single dose of a drug (typically any life saving drug). These are easy to use and are intended either for self-administration or by untrained personnel. The commercially available auto-injectors are majorly used for the management of anaphylaxis, multiple sclerosis and rheumatoid arthritis. High prevalence of anaphylaxis and food allergies is the major factor propelling the growth of the global auto-injectors market. According to the European Academy of Allergy and Clinical Immunology (EAACI), there has been a seven-fold increase in anaphylaxis related hospital admissions in Europe from 2003 to 2013. Similarly, the Australasian Society of Clinical Immunology and Allergy (ASCIA) stated that the number of anaphylaxis associated hospital admissions increased five times from 2004 to 2014 in New Zealand and Australia. Rising prevalence of anaphylaxis and food allergies is increasing the demand for epinephrine auto-injectors used for anaphylaxis management. Moreover, Healthline Networks, a provider of health information and technology solutions for advertisers, publishers, employers, and health plans and healthcare providers, stated that 2.5 million people were suffering from multiple sclerosis in 2013 worldwide. High prevalence of multiple sclerosis and rheumatoid arthritis is increasing the demand for novel treatment options among the patients, which in turn drives demand for auto-injectors globally.

Based on product types, the global auto-injectors market has been categorized into prefilled auto-injectors and fillable auto-injectors. Prefilled auto-injectors dominate the auto-injectors market due to their offered ease-of-use and rising patient awareness. Based on Therapeutic Applications, the global auto-injectors market has been segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The anaphylaxis segment was the leading and fastest growing market majorly due to high prevalence of the disease, rising awareness about epinephrine auto-injectors and advantages of its use for anaphylaxis management during emergency situations. Based on the manufacturing design, the auto-injectors market has been segmented into standardized auto-injectors and customized auto-injectors. Standardized auto-injectors dominated the market in 2013, as these are the oldest and most preferred auto-injectors with an established record of effective results. However, customized auto-injectors is estimated to be the fastest growing segment, as these offer customization of the dosage of the drug according to age, sex and need of the patient.

Get a Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

Geographically, the global auto-injectors market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global auto-injectors market in 2013 due to high prevalence of anaphylaxis, favorable government reimbursement policies and economic stability to purchase expensive auto-injectors in the region. On the other hand, Asia Pacific is estimated to be the most promising market for auto-injectors during the forecast period due to rising prevalence of anaphylaxis and multiple sclerosis in New Zealand and Australia coupled with the government reimbursement options in New Zealand, and rising awareness about novel treatment methods available in the market.

The auto-injectors market is consolidated and dominated by a few market players. Mylan, Inc. and Sanofi led the standardized auto-injectors segment due to higher demand for EpiPen and Auvi-Q auto-injectors, respectively. However, the SHL Group dominated the customized auto-injectors segment, with a wide product offering of prefilled customized auto-injectors. The other major companies operating in the auto-injectors market include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Novartis International AG, Pfizer, Inc., Unilife Corporation and Ypsomed Holdings AG. The auto-injectors market is innovation driven, therefore market players are constantly engaged in research and development activities in order to develop new and effective auto-injectors against various diseases.